Clinical trials: Daratumumab
Multiple Myeloma
Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma
Multiple myeloma (MM), a plasma cell disorder, is the second most common hematologic malignancy in the U.S. No standard curative therapy has yet been found.
- Trial name
- MASTER (NCT03224507)
- Testing
- KRdD followed by auto-HCT, KRdD only
- Where
- 4 sites in United States
- Volunteers
- 123 people
- Sponsor
- University of Alabama at Birmingham
Multiple Myeloma
A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma
The purpose of this study is to identify recommended Phase 2 doses (RP2Ds) for each treatment combination (between daratumumab plus talquetamab and teclistamab plus daratumumab with or without pomalidomide) and to characterize…
- Trial name
- NCT04108195
- Testing
- Daratumumab, Talquetamab, Teclistamab
- Where
- 24 sites in United States, Canada and 3 more
- Volunteers
- 290 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma, Amyloidosis
APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma
This is a Phase Ib/II, open-label, multi-center study evaluating the safety, tolerability, efficacy, and PK/ Pharmacodynamics of APG-2575 in combination with Pd/DRd in patients with relapsed/refractory (RR) multiple myeloma (MM).
- Trial name
- NCT04942067
- Testing
- APG-2575+ Pd, APG-2575 + DRd
- Where
- 3 sites in United States
- Volunteers
- 108 people
- Sponsor
- Ascentage Pharma Group Inc.
AL Amyloidosis
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
This phase III trial compares the effect of adding a stem cell transplant with melphalan after completing chemotherapy with daratumumab, cyclophosphamide, bortezomib and dexamethasone (Dara-VCD) versus chemotherapy with Dara-VCD…
- Trial name
- NCT06022939
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Biopsy, Biospecimen Collection
- Where
- 117 sites in United States
- Volunteers
- 338 people
- Sponsor
- SWOG Cancer Research Network
Relapsed or Refractory Multiple Myeloma
A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to evaluate the safety, tolerability, and preliminary anti-tumor activity of forimtamig when administered alone or in combination with carfilzomib or daratumumab or other combination partners in…
- Trial name
- NCT06055075
- Testing
- Forimtamig, Carfilzomib, Daratumumab
- Where
- 8 sites in Australia, Canada and 4 more
- Volunteers
- 21 people
- Sponsor
- Hoffmann-La Roche
Multiple Myeloma
MUK Nine b: OPTIMUM Treatment Protocol
To determine whether a combination of four novel agents bortezomib(Velcade), lenalidomide (Revlimid), Daratumumab (Darzalex) \& dexamethasone in combination with low-dose cyclophosphamide is sufficiently active in a high risk…
- Trial name
- MUKnineb (NCT03188172)
- Testing
- Cyclophosphamide, Bortezomib, Lenalidomide
- Where
- 21 sites in United Kingdom
- Volunteers
- 95 people
- Sponsor
- University of Leeds
Microsatellite Unstable Colorectal Cancer, Microsatellite Stable Colorectal Cancer
A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread
The purpose of this study is to examine if Nivolumab by itself, or Nivolumab in combination with other anti-cancer drugs, will result in meaningful tumor size reduction, in participants with colon cancer that has come back or has…
- Conditions
- Microsatellite Unstable Colorectal Cancer, Microsatellite Stable Colorectal Cancer, Mismatch Repair Proficient Colorectal Cancer, Mismatch Repair Deficient Colorectal Cancer
- Trial name
- CheckMate142 (NCT02060188)
- Testing
- Ipilimumab, Nivolumab, Cobimetinib
- Where
- 32 sites in United States, Australia and 6 more
- Volunteers
- 385 people
- Sponsor
- Bristol-Myers Squibb
Multiple Myeloma
Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
The study will investigate the effects of adding carfilzomib to the combination of pomalidomide and dexamethasone in sequential dose escalation cohorts in patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT01665794
- Testing
- Pomalidomide, Carfilzomib, dexamethasone
- Where
- 5 sites in United States, Canada
- Volunteers
- 25 people
- Sponsor
- University of Chicago
Relapsed Multiple Myeloma, Relapsed-Refractory Multiple Myeloma
Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma
This was a randomized, controlled, open-label, Phase 3 multicenter study which enrolled patients with Relapsed-Refractory Multiple Myeloma (RRMM) who were either double refractory to an Immunomodulatory Drug (IMiD) and a…
- Trial name
- LIGHTHOUSE (NCT04649060)
- Testing
- Melflufen, Dexamethasone, Daratumumab
- Where
- 26 sites in Bulgaria, Czechia and 9 more
- Volunteers
- 54 people
- Sponsor
- Oncopeptides AB
Lupus Nephritis
Daratumumab to Treat Active Lupus Nephritis
The purpose of this research is to study the safety and efficacy of daratumumab in inducing complete or partial remission in patients with active lupus nephritis.
- Trial name
- NCT04868838
- Testing
- Daratumumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Mayo Clinic
Waldenström Macroglobulinemia
A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia
This research study is studying Daratumumab as a possible treatment for Waldenström Macroglobulinemia.
- Trial name
- NCT03187262
- Testing
- Daratumumab
- Where
- 5 sites in United States
- Volunteers
- 13 people
- Sponsor
- Dana-Farber Cancer Institute
Multiple Myeloma
A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma
The purpose of this study is to identify recommended Phase 3 doses (RP3D) for treatment combination (GR1803 injection plus anti-CD38 monoclonal antibody) and to characterize the efficacy of RP3D for the treatment combination.
- Trial name
- NCT07090954
- Testing
- GR1803 injection, Anti-CD38 Monoclonal Antibody
- Where
- 2 sites in China
- Volunteers
- 32 people
- Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Multiple Myeloma
Daratumumab for First Line Treatment of Transplant-ineligible Myeloma Patients Followed by Daratumumab Re-treatment at First Relapse
Daratumumab for first line treatment of transplant-ineligible myeloma patients followed by daratumumab re-treatment at first relapse (GMMG-DADA)
- Trial name
- GMMG-DADA (NCT04656951)
- Testing
- Daratumumab
- Where
- Germany
- Volunteers
- 67 people
- Sponsor
- University of Cologne
Nephrotic Syndrome in Children
A Study of Anti-CD38 Monoclonal Antibody (SG301) Subcutaneous Injection in Children With Nephrotic Syndrome With Frequent Relapses or Steroid Dependence
This is an open - label study to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of SG301 Subcutaneous injection in children with frequently relapsing or steroid - dependent nephrotic syndrome.
- Trial name
- NCT07087314
- Testing
- SG301 Subcutaneous injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Mao Jianhua
Immune Thrombocytopenia, Treatment
Anti-CD38 Antibody Treating Elderly Patients With Primary Immune Thrombocytopenia (ITP)
To evaluate the safety and efficacy of Anti-CD38 Antibody in the treatment of elderly patients with primary immune thrombocytopenia in patients who have failed multiple treatment.
- Trial name
- NCT07063199
- Testing
- Daratumumab Injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma
This phase I/II trial studies the side effects and best dose of venetoclax when given together with daratumumab, bortezomib, and dexamethasone, and how well they work in treating patients with multiple myeloma that has come back…
- Trial name
- NCT03701321
- Testing
- Bortezomib, Daratumumab, Dexamethasone
- Where
- 3 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Adult Patients With Adverse Risk Acute Myeloblastic Leukemia
Escalation of Doses of Daratumumab in Combination With Chemotherapy (Idarubicin and Cytarabine or CPX-351) in Patients of 60 Years Old or More With Adverse Risk Acute Myeloblastic Leukemia (AML) (DARALAM)
To search for a Maximum Tolerated Dose (MTD) for the combination of daratumumab and induction chemotherapy with Idarubicin and cytarabine or CPX-351 in patients with Acute Myeloblastic Leukemia (AML) of poor prognosis
- Trial name
- DARALAM (NCT05749276)
- Testing
- Darzalex
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Nantes University Hospital
Multiple Myeloma
First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody
The purpose of this study is to test 89Zr-DFO-daratumumab, a new imaging agent, to demonstrate its safety and ability to take pictures of the myeloma.
- Trial name
- NCT03665155
- Testing
- 89Zr-daratumumab, PET/CT scans, Blood draws
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
De Novo Multiple Myeloma, Anitocabtagene Autoleucel
Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST)
The goal of this clinical trial is to learn if anitocabtagene autoleucel following induction therapy works to treat adult participants with newly diagnosed multiple myeloma.
- Trial name
- GEM-AnitoFIRST (NCT07045909)
- Testing
- Daratumumab, Isatuximab, Bortezomib
- Where
- 10 sites in Spain
- Volunteers
- 30 people
- Sponsor
- PETHEMA Foundation
Multiple Myeloma
A Prospective Study Comparing DRd With VRd-lite in Elderly Newly Diagnosed Multiple Myeloma
The purpose of the study is to compare the efficacy and safety of daratumumab, lenalidomide and dexamethasone (DRd) to that of modified bortezomib, lenalidomide and dexamethasone (VRd-lite), in terms of progression-free survival…
- Trial name
- NCT06497738
- Where
- 6 sites in China
- Volunteers
- 112 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University